Biorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.
Follow BRTX
Biorestorative Therapies, Inc. (BRTX) EV/Sales
As of 16 October 2026, Biorestorative Therapies, Inc. (BRTX) trades at a EV/Sales of −5.7×. Over the past ten years it has ranged from −449× (January 2022) to 94.4× (October 2021); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −6.2× | — |
| FY2024 | −24.9× | — |
| FY2023 | −72.1× | — |
| FY2022 | −117× | — |
| FY2021 | −447× | — |
| FY2020 | 22.7× | 1,729.92% |
| FY2019 | 1.2× | (82.02%) |
| FY2018 | 6.9× | (54.26%) |
| FY2017 | 15.1× | (66.21%) |
| FY2016 | 44.7× | 20,647.93% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | −8.8× | — |
| Dec 2025 | −6.2× | — |
| Sep 2025 | −9.5× | — |
| Jun 2025 | −10.7× | — |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −54.6× |
| BRTX Biorestorative Therapies, Inc. | −5.7× |
| CLSDQ Clearside Biomedical, Inc. compare | −1.2× |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. compare | 3.6× |
| TRVN Trevena, Inc. compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)